Adjuvants: Progress, regress and pandemic preparedness

Expert Review of Vaccines

Volumn 6, Issue 5, 2007, Pages 651-652

  Glenn, Gregory M ^a   O'Hagan, Derek T ^b  

^a IOMAI Corporation   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; AS 04; CORIXA; CPG OLIGODEOXYNUCLEOTIDE; FOCETRIA; HEPATITIS B VACCINE; IC 31; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MPL; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NASALFLU; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; DRUG APPROVAL; DRUG EFFICACY; EDITORIAL; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOPOTENTIATION; INFLUENZA; LICENSING; MALARIA; PANDEMIC; PRIORITY JOURNAL; PROCESS DEVELOPMENT; TRAVELLER DIARRHEA; VACCINATION;

ADJUVANTS, PHARMACEUTIC; ANIMALS; DISASTER PLANNING; DISEASE OUTBREAKS; HUMANS; PUBLIC POLICY; VACCINES;

EID: 35348960396     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.5.651     Document Type: Editorial

References (0)